Shares of Pfizer (PFE) have been steadily trending lower in recent weeks. The company has its hands in many pies with intriguing drugs that can help power sales growth for many years to come. However, the depressed valuation seems to imply that Pfizer will hit a growth funk once the COVID-19 pandemic winds down. After Pfizer's latest earnings result, the stock is trading at a mere 9.5 times trailing earnings — well below the pharma industry average of nearly 23 times. Going into a recession or slowdown, biopharma stocks should be in high demand.
https://www.tipranks.com/news/article/pfizer-stock-way-too-cheap-to-ignore-despite-recent-headwinds?utm_source=advfn.com&utm_medium=referral
Pfizer (NYSE:PFE)
過去 株価チャート
から 8 2022 まで 9 2022 Pfizerのチャートをもっと見るにはこちらをクリック
Pfizer (NYSE:PFE)
過去 株価チャート
から 9 2021 まで 9 2022 Pfizerのチャートをもっと見るにはこちらをクリック